Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY A SINGER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1932210671
CMS profile
43005
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$233,439.00

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
TG Therapeutics, Inc. $71,396.10 37
EMD Serono, Inc. $50,781.28 28
Genentech USA, Inc. $37,950.48 43
GENZYME CORPORATION $20,961.50 3
Biogen, Inc. $19,774.56 23
Alexion Pharmaceuticals, Inc. $11,053.59 12
E.R. Squibb & Sons, L.L.C. $9,837.35 7
Novartis Pharmaceuticals Corporation $7,068.48 20
Vanda Pharmaceuticals Inc. $4,174.99 2
Celgene Corporation $280.86 10
ABBVIE INC. $95.12 4
Amgen Inc. $20.35 1
Lilly USA, LLC $15.84 1
Cycle Pharmaceuticals Inc $14.45 1
PFIZER INC. $14.05 1

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY A SINGER

NPI 1932210671 · CMS profile ID 43005

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932210671?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY A SINGER, NPI 1932210671, CMS profile ID 43005. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932210671?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BARRY A SINGER, NPI 1932210671, CMS profile ID 43005. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932210671?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BARRY A SINGER, NPI 1932210671, CMS profile ID 43005, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932210671?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $233,439.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $334.6006/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236912507 CMS
EMD Serono, Inc. $25.6106/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236923430 CMS
EMD Serono, Inc. $445.9606/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236923840 CMS
EMD Serono, Inc. $384.7606/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236924276 CMS
GENZYME CORPORATION $3,955.0006/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233284445 CMS
EMD Serono, Inc. $2,923.0006/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236912483 CMS
E.R. Squibb & Sons, L.L.C. $685.0005/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1184895626 CMS
Alexion Pharmaceuticals, Inc. $1,775.0005/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202932044 CMS
Novartis Pharmaceuticals Corporation $532.6905/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200384970 CMS
Novartis Pharmaceuticals Corporation $172.9905/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200424919 CMS
Novartis Pharmaceuticals Corporation $5,950.0005/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200424921 CMS
Novartis Pharmaceuticals Corporation $17.4005/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200424923 CMS
Novartis Pharmaceuticals Corporation $28.0005/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200424925 CMS
EMD Serono, Inc. $10,855.0005/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236867536 CMS
EMD Serono, Inc. $91.7605/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236924526 CMS
EMD Serono, Inc. $4,593.0005/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236923276 CMS
Cycle Pharmaceuticals Inc $14.4504/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248905544 CMS
TG Therapeutics, Inc. $143.4804/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226255982 CMS
TG Therapeutics, Inc. $4,185.0004/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226255990 CMS
TG Therapeutics, Inc. $133.9704/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226256002 CMS
TG Therapeutics, Inc. $26.8304/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226256232 CMS
TG Therapeutics, Inc. $12.4404/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226256239 CMS
TG Therapeutics, Inc. $50.6804/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226256248 CMS
Genentech USA, Inc. $392.9604/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211497467 CMS
Genentech USA, Inc. $74.0604/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211497469 CMS
Genentech USA, Inc. $30.5004/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211497471 CMS
Genentech USA, Inc. $73.9304/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211497473 CMS
Genentech USA, Inc. $238.2604/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211497475 CMS
Genentech USA, Inc. $6,525.0004/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211497477 CMS
Genentech USA, Inc. $95.8304/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211497479 CMS
Genentech USA, Inc. $23.2404/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211497481 CMS
TG Therapeutics, Inc. $104.9004/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226256224 CMS
TG Therapeutics, Inc. $315.5304/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226256253 CMS
TG Therapeutics, Inc. $3,712.5004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226256019 CMS
EMD Serono, Inc. $80.7104/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236924204 CMS
EMD Serono, Inc. $2,923.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236922595 CMS
TG Therapeutics, Inc. $675.0004/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226255940 CMS
Novartis Pharmaceuticals Corporation $31.8303/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200384998 CMS
Novartis Pharmaceuticals Corporation $0.7803/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200385000 CMS
EMD Serono, Inc. $89.1703/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236896722 CMS
EMD Serono, Inc. $31.2203/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236900659 CMS
EMD Serono, Inc. $31.2103/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236900695 CMS
EMD Serono, Inc. $60.0103/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236918300 CMS
Celgene Corporation $183.6103/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184895614 CMS
EMD Serono, Inc. $243.6303/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236919056 CMS
Biogen, Inc. $24.7303/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208467719 CMS
Novartis Pharmaceuticals Corporation $30.2603/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200384996 CMS
ABBVIE INC. $20.9003/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204307125 CMS
E.R. Squibb & Sons, L.L.C. $2,055.0003/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1184895604 CMS
EMD Serono, Inc. $32.5203/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236916458 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $495,818.42 395
PY2020 $219,572.47 173
PY2021 $212,668.22 186
PY2022 $302,242.52 274
PY2023 $226,158.85 232
PY2024 $254,633.97 260
PY2025 $233,439.00 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,250.00 1
PY2025 Principal investigator $154,972.86 21
PY2024 Principal investigator $96,555.86 17
PY2023 Recipient $20,938.91 1
PY2023 Principal investigator $177,645.96 22
PY2022 Principal investigator $137,295.80 22
PY2021 Recipient $1,875.00 1
PY2021 Principal investigator $135,219.82 26
PY2020 Recipient $3,162.27 11
PY2020 Principal investigator $477,295.41 40
PY2019 Recipient $12,484.80 36
PY2019 Principal investigator $212,700.99 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $28,167.76 12/09/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199571
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 11/25/2025 Non-covered Recipient Entity
THE MS CENTER FOR INNOVATIONS IN CARE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199979
Principal investigator 1 GENZYME CORPORATION $9,024.00 11/17/2025 Non-covered Recipient Entity
Physicians Group Lc Bjc Medical Group Of Mo
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138889
Principal investigator 1 GENZYME CORPORATION $6,858.00 11/17/2025 Non-covered Recipient Entity
Physicians Group Lc Bjc Medical Group Of Mo
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138893
Principal investigator 1 TG Therapeutics, Inc. $3,860.00 11/01/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199569
Principal investigator 1 GENZYME CORPORATION $14,858.00 10/14/2025 Non-covered Recipient Entity
Physicians Group Lc Bjc Medical Group Of Mo
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138885
Principal investigator 1 TG Therapeutics, Inc. $4,140.00 08/31/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199519
Principal investigator 1 GENZYME CORPORATION $3,341.00 08/04/2025 Non-covered Recipient Entity
Physicians Group Lc Bjc Medical Group Of Mo
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138873
Principal investigator 1 GENZYME CORPORATION $4,347.00 08/04/2025 Non-covered Recipient Entity
Physicians Group Lc Bjc Medical Group Of Mo
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138876
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 08/04/2025 Non-covered Recipient Entity
THE MS CENTER FOR INNOVATIONS IN CARE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199975
Principal investigator 1 TG Therapeutics, Inc. $2,530.00 07/31/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199517
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 07/14/2025 Non-covered Recipient Entity
THE MS CENTER FOR INNOVATIONS IN CARE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199973
Principal investigator 1 GENZYME CORPORATION $3,517.00 07/02/2025 Non-covered Recipient Entity
Physicians Group Lc Bjc Medical Group Of Mo
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138870
Principal investigator 1 TG Therapeutics, Inc. $4,970.00 06/01/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199461
Principal investigator 1 GENZYME CORPORATION $11,517.00 05/19/2025 Non-covered Recipient Entity
Physicians Group Lc Bjc Medical Group Of Mo
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138867
Principal investigator 1 TG Therapeutics, Inc. $3,960.00 05/01/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199459
Principal investigator 1 TG Therapeutics, Inc. $3,570.00 03/31/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199457
Principal investigator 1 TG Therapeutics, Inc. $1,610.00 02/28/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199455
Principal investigator 1 TG Therapeutics, Inc. $3,469.18 02/12/2025 Non-covered Recipient Entity
THE MS CENTER FOR INNOVATIONS IN CARE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199933
Recipient GENZYME CORPORATION $1,250.00 02/11/2025 Covered Recipient Physician A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) No dispute reported 06/30/2026 1226102296
Principal investigator 1 TG Therapeutics, Inc. $3,690.00 01/31/2025 Non-covered Recipient Entity
MS Center for Innovations in Care at Missouri Baptist Medical Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199453
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,804.98 01/09/2025 Non-covered Recipient Entity
THE MS CENTER FOR INNOVATION IN CARE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190306849